Triple-Drug attack shows promise against multiple myeloma

NCT ID NCT02441686

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 study tested a combination of three drugs—lenalidomide, bortezomib, and dexamethasone (RVD)—in 46 people newly diagnosed with multiple myeloma. The goal was to see how well the drugs worked before a stem cell transplant. The study measured response rates and side effects like nerve damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide, bortezomib, and dexamethasone (RVD combination)
What this could lead to: If successful, this combination could become a standard initial treatment for newly diagnosed multiple myeloma, improving response rates before stem cell transplant.
What could go wrong: This is a small Phase 2 trial with only 46 participants, so results may not apply to all patients. Side effects like nerve damage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Eastern Maine Medical Center

Brewer, Maine, 04412, United States
Hematology Oncology of Northern New Jersey

Morristown, New Jersey, 07962, United States
Massachusetts General Hosptial

Boston, Massachusetts, 02114, United States
Virgina Piper Cancer Institute

Minneapolis, Minnesota, 55407, United States
Virginia Piper Cancer Institute

Coon Rapids, Minnesota, 55433, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.